Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Algeta completes phase II trial with Alpharadin for treating bone metastases in advanced prostate cancer

Algeta ASA has announced that with the results of the BC1-04 study reported today it has completed its comprehensive phase II clinical program evaluating Alpharadin (radium-223) as a new treatment for bone metastases in patients with hormone-refractory prostate cancer (HRPC).

15 Jan 2009

Theraputic target for prostate cancer

The report, entitled Cytosolic Phospholipase A2-: A Potential Therapeutic Target for Prostate Cancer, describes the possible role of an enzyme called cPLA2- in prostate cancer and its potential to be a treatment target for prostate cancers that no longer respond to hormone-related therapy.

14 Jan 2009

Natural 'defence' gene reveals how oestrogen fuels cancer

CANCER RESEARCH UK scientists have shown for the first time how a natural 'defence' gene involved in fighting infections such as common colds, can be triggered by hormones to ignite and drive cancers like breast, ovarian, and possibly prostate cancer. Their findings are published in the Journal of Experimental Medicine.

13 Jan 2009

Researchers find genes that fuse in cancer

Using new technologies that make it easier to sequence the human genome, researchers at the University of Michigan Comprehensive Cancer Center have identified a series of genes that become fused when their chromosomes trade places with each other.

12 Jan 2009

New evidence suggests preventive effect of herbal supplement in prostate cancer

DHEA is a natural circulating hormone and the body's production of it decreases with age.

12 Jan 2009

Statistical analysis of bladder cancer

Bladder cancer is much more likely to be deadly for women and African-Americans, but the reasons long believed to explain the phenomenon account for only part of the differences for such patients compared to their white and male counterparts, according to results published in the Jan. 1 issue of the journal Cancer.

9 Jan 2009

Novel low-cost immunotherapy for cancer cells

Molecules of sugar sitting on the surface of cancer cells are keys to the development of a new vaccine aimed at both treating and stopping the spread of certain types of cancers called carcinomas, which include prostate, breast, ovarian and lung, among others.

8 Jan 2009

Latest genetic research on ADHD

A special issue of American Journal of Medical Genetics (AJMG): Part B: Neuropsychiatric Genetics presents a comprehensive overview of the latest progress in genetic research of Attention Deficit/Hyperactivity Disorder (ADHD).

7 Jan 2009

Metadherin gene linked to metastasis of breast cancer

A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all breast cancer patients, spreading the disease, resisting traditional chemotherapies and eventually leading to death.

5 Jan 2009

Old Digitalis-based drugs show promise as a treatment for cancer

Digitalis-based drugs like digoxin have been used for centuries to treat patients with irregular heart rhythms and heart failure and are still in use today.

5 Jan 2009

Endo Pharmaceuticals to acquire Indevus Pharmaceuticals

Endo Pharmaceuticals (NASDAQ:ENDP) and Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones.

5 Jan 2009

First-degree family history of prostate cancer does not affect some treatment outcomes

In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics similar to men with no family history at all, according to a January 1 study in the International Journal of Radiation Oncology*Biology*Physics , the official journal of the American Society for Radiation Oncology.

5 Jan 2009

Why prostate cancer patients fail hormone deprivation therapy

The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years.

1 Jan 2009

Extract from grapes kills lab leukemia cells, proving value of natural compounds

An extract from grape seeds forces laboratory leukemia cells to commit cell suicide, according to researchers from the University of Kentucky.

1 Jan 2009

FDA approves injectable drug degarelix for advanced prostate cancer

The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer.

29 Dec 2008

Barcode chip enables cheaper, faster blood testing

A new barcode chip developed by a multi-institutional team of investigators promises to revolutionize diagnostic medical testing. In less than 10 minutes and using just a pinprick's worth of blood, the chip can measure the concentrations of dozens of proteins, including those that herald the presence of diseases such as cancer and heart disease.

29 Dec 2008

Cancer is on the increase in Australia

The report shows that the number of new cancer cases diagnosed in Australia each year passed the 100,000 mark for the first time in 2005 and the number of new cases in 2008 is estimated to be over 108,000.

22 Dec 2008

Trial looks at high intensity focused ultrasound for locally recurrent prostate cancer

A Phase III clinical trial at New York University is investigating the safety and efficacy of High Intensity Focused Ultrasound (HIFU) for the treatment of locally recurrent prostate cancer following failed external beam radiation therapy (EBRT) using the Sonablate(R) 500.

22 Dec 2008

Ingredient in cough medicine could treat prostate cancer

A study published today in the December issue of the European medical journal Anticancer Research demonstrates that an ingredient used in a common cough suppressant may be useful in treating advanced prostate cancer.

22 Dec 2008

Merck KGaA acquires manufacturing rights for Stimuvax from Oncothyreon

Oncothyreon Inc. announced today that Merck KGaA of Darmstadt, Germany has licensed the right to manufacture Stimuvax and, through its affiliate EMD Serono Canada Inc., purchased current inventory and certain assets utilized for the manufacture of Stimuvax from Oncothyreon for consideration which includes net payments to Oncothyreon totaling approximately U.S. $13 million.

18 Dec 2008